Tech Company Financing Transactions
Corteria Pharmaceuticals Funding Round
Corteria Pharmaceuticals, based in Paris, secured $69.6 million from Jeito Capital, OrbiMed and Fountain Healthcare Partners.
Transaction Overview
Company Name
Announced On
9/7/2023
Transaction Type
Venture Equity
Amount
$69,640,000
Round
Series A
Investors
Jeito Capital (Lead Investor) (Andreas Wallnoefer)
OrbiMed (Lead Investor) (Erez Chimovits)
Proceeds Purpose
The company intends to use the funds to advance its cardiovascular pipeline into the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
128 rue de la Boétie
Paris, 75008
FR
Paris, 75008
FR
Phone
Undisclosed
Website
Email Address
Overview
Founded in 2021, Corteria Pharmaceuticals is a privately held company developing first-in-class drugs for indications of high unmet medical need, such as heart failure, sarcopenia and obesity subpopulations. Our strategy implies innovative patient stratification and target selection based on human evidence and a better understanding of the disease biology in patients. We are using cutting-edge methods to stratify the patients and identify those who will benefit the most from our treatments. Our focus is on worsening and acute heart failure, right heart failure, sarcopenia (including age-related sarcopenia and obesity-related sarcopenia) and obesity with established complications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Philip Janiak
Browse more venture capital transactions:
Prev: 9/7/2023: Testaify venture capital transaction
Next: 9/7/2023: Certa venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs